# Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer

> **NCT00140400** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cell Genesys** · enrollment: 50 (—)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** Immunotherapy allogeneic GM-CSF secreting cellular vaccine

## Key facts

- **NCT ID:** NCT00140400
- **Lead sponsor:** Cell Genesys
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-05
- **Primary completion:** —
- **Final completion:** 2001-01
- **Target enrollment:** 50 (—)
- **Last updated:** 2005-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00140400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00140400, "Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00140400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*